| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |